RxDoctor Payments Data

Elan Salzhauer, MD

Urology · Liverpool, NYNPI 1518915040

Payments from drug & device makers

$21,044in general payments, 2019–2025

Across 323 payments — averaging $65.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Coloplast$4K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
  • Astellas Pharma US Inc$749
  • Urogen Pharma, Inc.$682
  • Myriad Genetic Laboratories, Inc.$609
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$6,78532%
  • Travel & lodging$1,6268%
  • Food & beverage$8,09138%
  • Education$4,52622%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,044 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$311,785
Medicare patients
1,017
Services billed
3,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron95$96,481
GemtesaVibegron43$40,902
Mirabegron ErMirabegron31$26,014
Tamsulosin Hcl438$5,446
PremarinEstrogens, Conjugated12$5,110
Potassium Citrate ErPotassium Citrate25$3,824
Testosterone21$3,801
Silodosin38$2,529
Finasteride134$1,808
Alfuzosin Hcl ErAlfuzosin Hcl55$1,635
Cefpodoxime Proxetil52$1,456
Dutasteride36$1,340
Estradiol21$1,133
Methenamine Hippurate11$1,063
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$749$96,48195 claims
PfizerPremarin$162$5,11012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.

Other urology in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →